[ARTICLE WITHDRAWN] Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia Via Targeting MiR-184

Overview

Journal Oncol Res

Specialty Oncology

Date 2017 Jun 28

PMID 28653609

Citations 20

Affiliations

Soon will be listed here.

Abstract

THIS ARTICLE WAS WITHDRAWN BY THE PUBLISHER IN 03/2021. We submitted a manuscript entitled "Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184", which was published in the 26(2) issue of Oncology Research. But now we found some inaccuracies in this manuscript. So after carefully thinking, we are going to withdraw manuscript and try to give more precise model. Thus we decided to withdraw this manuscript with great pity. We sincerely say sorry for all the staffs involved this manuscript because of our action. All authors agree to withdraw this manuscript. Thank you very much for your time and kind consideration. Thanks for your time and best wishes. Li Jingdong.

Citing Articles

A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers.

Xu J, Wang X, Zhu C, Wang K Front Cell Dev Biol. 2022; 10:997633.

PMID: 36544907 PMC: 9760833. DOI: 10.3389/fcell.2022.997633.

Diagnostic and Therapeutic Implications of Long Non-Coding RNAs in Leukemia.

Gasic V, Karan-Djurasevic T, Pavlovic D, Zukic B, Pavlovic S, Tosic N Life (Basel). 2022; 12(11).

PMID: 36362925 PMC: 9695865. DOI: 10.3390/life12111770.

Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184.

Guo X, Wang Z, Deng X, Lu Y, Huang X, Lin J Cell Cycle. 2022; 21(15):1557-1577.

PMID: 35400275 PMC: 9291649. DOI: 10.1080/15384101.2022.2057633.

Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis.

Liu Y, Chen Q, Zhu Y, Wang T, Ye L, Han L Cell Death Discov. 2021; 7(1):210.

PMID: 34381023 PMC: 8358062. DOI: 10.1038/s41420-021-00596-9.

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.

Shamaa M FEBS Open Bio. 2020; 11(3):588-597.

PMID: 33289342 PMC: 7931239. DOI: 10.1002/2211-5463.13052.

References

Gao B, Gao K, Li L, Huang Z, Lin L . miR-184 functions as an oncogenic regulator in hepatocellular carcinoma (HCC). Biomed Pharmacother. 2013; 68(2):143-8. DOI: 10.1016/j.biopha.2013.09.005. View

Xing C, Hu X, Xie F, Yu Z, Li H, Bin-Zhou . Long non-coding RNA HOTAIR modulates c-KIT expression through sponging miR-193a in acute myeloid leukemia. FEBS Lett. 2015; 589(15):1981-7. DOI: 10.1016/j.febslet.2015.04.061. View

Yan Y, Liang H, Li T, Li M, Li R, Qin X . The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis. Tumour Biol. 2014; 35(4):3047-52. PMC: 3980037. DOI: 10.1007/s13277-013-1395-6. View

Hughes T, Saglio G, Quintas-Cardama A, Mauro M, Kim D, Lipton J . BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015; 29(9):1832-8. PMC: 4559757. DOI: 10.1038/leu.2015.168. View

Kuo C, Lai K, Ma Y, Weng S, Lin J, Chung J . Gallic acid inhibits migration and invasion of SCC-4 human oral cancer cells through actions of NF-κB, Ras and matrix metalloproteinase-2 and -9. Oncol Rep. 2014; 32(1):355-61. DOI: 10.3892/or.2014.3209. View

Xiu Y, Sun K, Chen X, Chen S, Zhao Y, Guo Q . Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3. Oncotarget. 2017; 8(19):31714-31725. PMC: 5458242. DOI: 10.18632/oncotarget.15955. View

Su Z, Chen D, Li Y, Zhang E, Yu Z, Chen T . microRNA-184 functions as tumor suppressor in renal cell carcinoma. Exp Ther Med. 2015; 9(3):961-966. PMC: 4316952. DOI: 10.3892/etm.2015.2199. View

Yao H, Duan M, Lin L, Wu C, Fu X, Wang H . TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population. Oncotarget. 2017; 8(11):18337-18347. PMC: 5392332. DOI: 10.18632/oncotarget.15440. View

Wang P, Ren Z, Sun P . Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem. 2012; 113(6):1868-74. DOI: 10.1002/jcb.24055. View

10.

Lucas C, Harris R, Holcroft A, Scott L, Carmell N, McDonald E . Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia. 2015; 29(7):1514-23. DOI: 10.1038/leu.2015.71. View

11.

Chen R, Huang Z, Liu L, Xiang M, Li G, Feng J . Involvement of endoplasmic reticulum stress and p53 in lncRNA MEG3-induced human hepatoma HepG2 cell apoptosis. Oncol Rep. 2016; 36(3):1649-57. DOI: 10.3892/or.2016.4919. View

12.

Jabbour E, Kantarjian H . Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014; 89(5):547-56. DOI: 10.1002/ajh.23691. View

13.

Zhang X, Zhou Y, Mehta K, Danila D, Scolavino S, Johnson S . A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003; 88(11):5119-26. DOI: 10.1210/jc.2003-030222. View

14.

Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y . Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res. 2014; 21(4):833-43. DOI: 10.1158/1078-0432.CCR-13-3317. View

15.

Perekhrestenko T, Diachenko M, Sviezhentseva I, Gordienko A, Bilko D . Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Georgian Med News. 2015; (240):43-50. View

16.

Magee P, Allsopp P, Samaletdin A, Rowland I . Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. Eur J Nutr. 2013; 53(1):345-50. DOI: 10.1007/s00394-013-0520-z. View

17.

Zhang X, Ding H, Han Y, Sun D, Wang H, Zhai X . The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma. Oncol Lett. 2016; 10(6):3510-3514. PMC: 4665810. DOI: 10.3892/ol.2015.3798. View

18.

Arora R, Sharma M, Monif T, Iyer S . A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets. Cancer Res Treat. 2016; 48(3):1120-9. PMC: 4946363. DOI: 10.4143/crt.2015.436. View

19.

Eiring A, Khorashad J, Anderson D, Yu F, Redwine H, Mason C . β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2015; 29(12):2328-37. PMC: 4675686. DOI: 10.1038/leu.2015.196. View

20.

Zhao H, Yuan X, Jiang J, Wang P, Sun X, Wang D . Antimetastatic effects of licochalcone B on human bladder carcinoma T24 by inhibition of matrix metalloproteinases-9 and NF-кB activity. Basic Clin Pharmacol Toxicol. 2014; 115(6):527-33. DOI: 10.1111/bcpt.12273. View